Overview

Gonorrhea Therapeutics Market is poised to value over USD 2 billion and register a CAGR close to 5% during the forecast period 2022 to 2028.

In sexually transmitted diseases (STDs), gonorrhea is the most common. An infection caused by Neisseria gonorrhoeae causes this condition. Infected areas of the body include the urethra, eyes, throat, vagina, anus, and female reproductive tract, all of which are warm, moist areas. Unprotected sex is the most common way to spread Gonorrhea from one person to another. A newborn can catch the infection from their mother during delivery if that mother is infected. The eyes are the most commonly affected part of the body when it comes to infants. A person usually experiences symptoms within two to 14 days of being exposed. It is however possible for people to be affected by gonorrhea and never develop obvious symptoms. It is more likely for people who do not have any symptoms of the infection to spread it to other partners. The gonorrhea therapeutics market is expected to grow in the forecast period due to driving factors such as the rising prevalence of gonorrhea and the growing awareness of STDs (sexually transmitted diseases). In addition, advances in relevant diagnostic methods, rising investments by major players, and growing demand are all providing opportunities for market growth over the next few years. Developing new drugs and focusing on quick approvals will remain key winning imperatives for stakeholders in the gonorrhea therapeutics market, complementing their brand repositioning strategies. 

FutureWise Market Research has instantiated a report that provides an intricate analysis of Gonorrhea Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Gonorrhea Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Gonorrhea Therapeutics Market:
• Hologic, Inc.
• Merck & Co.
• Pfizer Inc.
• AstraZeneca
• Danaher
• Abbott
• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Lupin Pharmaceuticals
• Teligent, Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Novartis AG.
• Allergan plc
• Sanofi S.A.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.  
• Baxter International Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Gonorrhea Therapeutics Market Segmentation:
By Gonococcal Infection
• Uncomplicated Gonococcal Infection
• Gonococcal Arthritis
• Gonococcal Meningitis and Endocarditis
By Treatment
• Monotherapy
• Dual Therapy
By Route of Administration
• Oral
• Injectable
By Gender
• Women
• Men
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Gonorrhea Therapeutics Market Video Sample:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Gonorrhea Therapeutics Market By Gonococcal Infection, By Treatment, By Route of Administration, By Gender, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Gonococcal Infection launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

    1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Gonorrhea Therapeutics Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Gonorrhea Therapeutics Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Gonorrhea Therapeutics Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Gonorrhea Therapeutics Market, By Gonococcal Infection Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Uncomplicated Gonococcal Infection
   7.2. Gonococcal Arthritis
   7.3. Gonococcal Meningitis and Endocarditis

8. Gonorrhea Therapeutics Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Monotherapy
   8.2. Dual Therapy

9. Gonorrhea Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Oral
   9.2. Injectable

10. Gonorrhea Therapeutics Market, By Gender Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Women
    10.2. Men

11. Gonorrhea Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
    11.1. Hospital Pharmacies
    11.2. Retail Pharmacies
    11.3. Online Pharmacies
    11.4. Others

12. North America Gonorrhea Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. U.S.A
          12.2.2. Canada
          12.2.3. Mexico
    12.3. Market Size (USD Million) Forecast for North America 2022-2028

13. Latin America Gonorrhea Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Brazil
          13.2.2. Venezuela
          13.2.3. Argentina
          13.2.4. Rest of Latin America
    13.3. Market Size (USD Million) Forecast for Latin America 2022-2028

14. Europe Gonorrhea Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Germany
          14.2.2. U.K         
          14.2.3. France
          14.2.4. Italy
          14.2.5. Spain
          14.2.6. Russia
          14.2.7. Poland
          14.2.8. Rest of Europe
    14.3. Market Size (USD Million) Forecast for Europe 2022-2028

15. Asia Pacific Gonorrhea Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. Japan
          15.2.2. China
          15.2.3. India
          15.2.4. Australia and New Zealand
          15.2.5. ASEAN
          15.2.6. Rest of Asia Pacific
    15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    16.1. Introduction
    16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          16.2.1. GCC
          16.2.2. Israel
          16.2.3. South Africa
          16.2.4. Rest of MEA
    16.3. Market Size (USD Million) Forecast for MEA 2022-2028

17. Market Share Analysis and Competitive Landscape   
    17.1. Global Landscape - Key Players, Revenue and Presence
    17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    17.3. Global Emerging Companies
    17.4. North America - Market Share Analysis and Key Regional Players
    17.5. Europe - Market Share Analysis and Key Regional Players
    17.6. Asia Pacific - Market Share Analysis and Key Regional Players
    17.7. Global Key Player - Growth Matrix

18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   18.1. Hologic, Inc.
         18.1.1. Company Overview
         18.1.2. Product Portfolio
         18.1.3. SWOT Analysis
         18.1.4. Financial Overview
         18.1.5. Strategic Overview
   18.2. Merck & Co., Inc.
         18.2.1. Company Overview
         18.2.2. Product Portfolio
         18.2.3. SWOT Analysis
         18.2.4. Financial Overview
         18.2.5. Strategic Overview
   18.3. Pfizer Inc.
         18.3.1. Company Overview
         18.3.2. Product Portfolio
         18.3.3. SWOT Analysis
         18.3.4. Financial Overview
         18.3.5. Strategic Overview
   18.4. AstraZeneca
         18.4.1. Company Overview
         18.4.2. Product Portfolio
         18.4.3. SWOT Analysis
         18.4.4. Financial Overview
         18.4.5. Strategic Overview
   18.5. Danaher
         18.5.1. Company Overview
         18.5.2. Product Portfolio
         18.5.3. SWOT Analysis
         18.5.4. Financial Overview
         18.5.5. Strategic Overview          
   18.6. Abbott
         18.6.1. Company Overview
         18.6.2. Product Portfolio
         18.6.3. SWOT Analysis
         18.6.4. Financial Overview
         18.6.5. Strategic Overview  
   18.7. Becton Dickinson and Company
         18.7.1. Company Overview
         18.7.2. Product Portfolio
         18.7.3. SWOT Analysis
         18.7.4. Financial Overview
         18.7.5. Strategic Overview    
   18.8. F. Hoffmann-La Roche Ltd.
         18.8.1. Company Overview
         18.8.2. Product Portfolio
         18.8.3. SWOT Analysis
         18.8.4. Financial Overview
         18.8.5. Strategic Overview
   18.9. Lupin Pharmaceuticals
         18.9.1. Company Overview
         18.9.2. Product Portfolio
         18.9.3. SWOT Analysis
         18.9.4. Financial Overview
         18.9.5. Strategic Overview
   18.10.Teligent, Inc.
         18.10.1. Company Overview
         18.10.2. Product Portfolio
         18.10.3. SWOT Analysis
         18.10.4. Financial Overview
         18.10.5. Strategic Overview
   18.11.Bayer AG
         18.11.1. Company Overview
         18.11.2. Product Portfolio
         18.11.3. SWOT Analysis
         18.11.4. Financial Overview
         18.11.5. Strategic Overview
   18.12.GlaxoSmithKline Plc.
         18.12.1. Company Overview
         18.12.2. Product Portfolio
         18.12.3. SWOT Analysis
         18.12.4. Financial Overview
         18.12.5. Strategic Overview
   18.13.Novartis AG
         18.13.1. Company Overview
         18.13.2. Product Portfolio
         18.13.3. SWOT Analysis
         18.13.4. Financial Overview
         18.13.5. Strategic Overview
   18.14.Allergan plc
         18.14.1. Company Overview
         18.14.2. Product Portfolio
         18.14.3. SWOT Analysis
         18.14.4. Financial Overview
         18.14.5. Strategic Overview
   18.15.Sanofi S.A.
         18.15.1. Company Overview
         18.15.2. Product Portfolio
         18.15.3. SWOT Analysis
         18.15.4. Financial Overview
         18.15.5. Strategic Overview
   18.16.Mylan N.V.
         18.16.1. Company Overview
         18.16.2. Product Portfolio
         18.16.3. SWOT Analysis
         18.16.4. Financial Overview
         18.16.5. Strategic Overview
   18.17.Teva Pharmaceutical Industries Ltd.
         18.17.1. Company Overview
         18.17.2. Product Portfolio
         18.17.3. SWOT Analysis
         18.17.4. Financial Overview
         18.17.5. Strategic Overview
   18.18.Baxter International Inc.
         18.18.1. Company Overview
         18.18.2. Product Portfolio
         18.18.3. SWOT Analysis
         18.18.4. Financial Overview
         18.18.5. Strategic Overview

19. Pre and Post COVID-19 Impact
    19.1. Positive influence on the healthcare industry
    19.2. The financial disruption of the manufacturing sector
    19.3. Impact of COVID-19 on emerging companies
    19.4. Significant mandates in the healthcare regulations initiated by administrations
    19.5. The overall economic slowdown of the developing and developed nations

20. FutureWise SME Key Takeaway Points for Client

Tables

Figures